BR112017023959B1 - Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus - Google Patents

Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus Download PDF

Info

Publication number
BR112017023959B1
BR112017023959B1 BR112017023959-0A BR112017023959A BR112017023959B1 BR 112017023959 B1 BR112017023959 B1 BR 112017023959B1 BR 112017023959 A BR112017023959 A BR 112017023959A BR 112017023959 B1 BR112017023959 B1 BR 112017023959B1
Authority
BR
Brazil
Prior art keywords
purin
methyl
amino
compound
propylsulfonimidoyl
Prior art date
Application number
BR112017023959-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112017023959A2 (pt
Inventor
Chungen Liang
Kun Miao
Jianping Wang
HongYing Yun
Xiufang Zheng
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55910966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017023959(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of BR112017023959A2 publication Critical patent/BR112017023959A2/pt
Publication of BR112017023959B1 publication Critical patent/BR112017023959B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112017023959-0A 2015-05-08 2016-05-04 Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus BR112017023959B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/078507 2015-05-08
CN2015078507 2015-05-08
CN2016078785 2016-04-08
CNPCT/CN2016/078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (2)

Publication Number Publication Date
BR112017023959A2 BR112017023959A2 (pt) 2018-07-17
BR112017023959B1 true BR112017023959B1 (pt) 2023-05-02

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017023959-0A BR112017023959B1 (pt) 2015-05-08 2016-05-04 Novos compostos de sulfonimidoilpurinona e derivados para o tratamento e profilaxia de infecção por vírus

Country Status (32)

Country Link
US (3) US9708325B2 (https=)
EP (1) EP3294740B1 (https=)
JP (1) JP6738352B2 (https=)
KR (1) KR102690131B1 (https=)
CN (1) CN107580596B (https=)
AR (1) AR104528A1 (https=)
AU (3) AU2016260683B2 (https=)
BR (1) BR112017023959B1 (https=)
CA (1) CA2982704C (https=)
CL (1) CL2017002745A1 (https=)
CO (1) CO2017009994A2 (https=)
CR (1) CR20170496A (https=)
DK (1) DK3294740T3 (https=)
ES (1) ES2753777T3 (https=)
HR (1) HRP20191942T1 (https=)
HU (1) HUE045906T2 (https=)
IL (2) IL254947B (https=)
LT (1) LT3294740T (https=)
MX (2) MX376761B (https=)
MY (1) MY182353A (https=)
NZ (2) NZ775222A (https=)
PE (1) PE20171620A1 (https=)
PH (1) PH12017502009A1 (https=)
PL (1) PL3294740T3 (https=)
PT (1) PT3294740T (https=)
RS (1) RS59435B1 (https=)
RU (1) RU2745269C2 (https=)
SG (1) SG10202108841YA (https=)
SI (1) SI3294740T1 (https=)
TW (2) TWI706954B (https=)
UA (1) UA120450C2 (https=)
WO (1) WO2016180695A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
CN109715214B (zh) 2016-09-13 2022-03-04 豪夫迈·罗氏有限公司 Tlr7激动剂和hbv衣壳组装抑制剂的组合治疗
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
RU2020131012A (ru) * 2018-02-28 2022-03-28 Ф. Хоффманн-Ля Рош Аг 7-замещенные соединения сульфонимидоилпуринонов и их производные для лечения и профилактики рака печени
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
JP7695885B2 (ja) * 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
JP7581336B2 (ja) 2019-09-20 2024-11-12 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 硫黄及びスルホキシミン含有置換基を有する殺有害生物的に活性な複素環式誘導体
US20230131192A1 (en) * 2020-01-27 2023-04-27 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
JP2023512204A (ja) * 2020-01-27 2023-03-24 ブリストル－マイヤーズ スクイブ カンパニー トール様受容体７（ＴＬＲ７）アゴニストとしての１Ｈ－ピラゾロ［４，３－ｄ］ピリミジン化合物
CN119604517A (zh) 2022-07-14 2025-03-11 豪夫迈·罗氏有限公司 用于治疗癌症的磷酰基嘌呤酮化合物
CN118724963A (zh) * 2023-03-30 2024-10-01 浙江养生堂天然药物研究所有限公司 含磷或含硫的大环化合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) * 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
ES2467108T3 (es) * 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
RS57851B1 (sr) * 2011-11-09 2018-12-31 Janssen Sciences Ireland Uc Purinski derivati za tretman viralnih infekcija
AU2014242954B2 (en) 2013-03-29 2018-03-15 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
PL3294740T3 (pl) * 2015-05-08 2020-03-31 F. Hoffmann-La Roche Ag Nowe sulfonoimidoilopurynony i pochodne do leczenia i profilaktyki infekcji wirusowych
AU2017320742B2 (en) * 2016-08-29 2021-08-05 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection

Also Published As

Publication number Publication date
PT3294740T (pt) 2019-10-29
CN107580596B (zh) 2020-07-14
AR104528A1 (es) 2017-07-26
NZ775222A (en) 2024-09-27
JP6738352B2 (ja) 2020-08-12
HUE045906T2 (hu) 2020-01-28
LT3294740T (lt) 2019-11-25
AU2016260683B2 (en) 2020-10-29
TW201716410A (zh) 2017-05-16
NZ735648A (en) 2023-06-30
SG10202108841YA (en) 2021-09-29
KR20180003612A (ko) 2018-01-09
EP3294740B1 (en) 2019-09-04
US11242345B2 (en) 2022-02-08
US20200109144A1 (en) 2020-04-09
US20170275286A1 (en) 2017-09-28
KR102690131B1 (ko) 2024-07-31
MX2017014033A (es) 2018-03-01
CN107580596A (zh) 2018-01-12
HK1247925A1 (zh) 2018-10-05
CR20170496A (es) 2017-12-05
CA2982704A1 (en) 2016-11-17
RU2745269C2 (ru) 2021-03-22
MX2020010949A (es) 2022-06-16
ES2753777T3 (es) 2020-04-14
UA120450C2 (uk) 2019-12-10
IL280769A (en) 2021-04-29
DK3294740T3 (da) 2019-11-04
MY182353A (en) 2021-01-20
MX393198B (es) 2025-03-19
TW202108584A (zh) 2021-03-01
AU2016260683A1 (en) 2017-10-12
RU2017142577A (ru) 2019-06-10
HRP20191942T1 (hr) 2020-01-10
MX376761B (es) 2025-03-07
IL254947A0 (en) 2017-12-31
RS59435B1 (sr) 2019-11-29
JP2018515509A (ja) 2018-06-14
IL280769B1 (en) 2023-03-01
US20160326177A1 (en) 2016-11-10
BR112017023959A2 (pt) 2018-07-17
TWI768467B (zh) 2022-06-21
PH12017502009A1 (en) 2018-03-26
EP3294740A1 (en) 2018-03-21
PL3294740T3 (pl) 2020-03-31
US9708325B2 (en) 2017-07-18
CA2982704C (en) 2023-10-24
CL2017002745A1 (es) 2018-05-18
SI3294740T1 (sl) 2019-12-31
TWI706954B (zh) 2020-10-11
RU2017142577A3 (https=) 2019-10-31
US10399983B2 (en) 2019-09-03
AU2020256348B2 (en) 2022-06-16
IL280769B2 (en) 2023-07-01
AU2022204666A1 (en) 2022-07-21
IL254947B (en) 2021-02-28
WO2016180695A1 (en) 2016-11-17
CO2017009994A2 (es) 2018-02-20
PE20171620A1 (es) 2017-11-02
AU2020256348A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
AU2020256348B2 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
TWI557127B (zh) 布魯頓氏酪胺酸激酶抑制劑
RU2751349C2 (ru) 7-замещенные сульфонимидоилпуриноны для лечения и профилактики вирусной инфекции
KR20220042431A (ko) 헤테로시클릭 rip1 키나제 억제제
TW201834657A (zh) 聚－adp核糖聚合酶（parp）抑制劑
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
WO2017071516A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
BR112016023554B1 (pt) Novos compostos macrocíclicos
CN113773335A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
TW202204351A (zh) 具有大環結構的化合物及其用途
JP2023538137A (ja) 芳香環ラクタム系化合物、その製造方法及び使用
HK1247925B (zh) 用於治疗和预防病毒感染的新的磺亚氨酰基嘌呤酮化合物和衍生物
TW202502763A (zh) 治療發炎性疾病之方法
CN119490507A (zh) 一种新型激酶抑制剂
TW202502326A (zh) 治療發炎性疾病之方法
HK1231076A1 (en) Macrocyclic compounds

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2016, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 10A ANUIDADE.